Evaluating The Annual Cost Per Response Rate of Pirfenidone And Nintedanib For The Treatment of Patients With Idiopathic Pulmonary Fibrosis
Oct 1, 2017, 00:00
10.1016/j.jval.2017.08.1472
https://www.valueinhealthjournal.com/article/S1098-3015(17)31806-5/fulltext
Title :
Evaluating The Annual Cost Per Response Rate of Pirfenidone And Nintedanib For The Treatment of Patients With Idiopathic Pulmonary Fibrosis
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(17)31806-5&doi=10.1016/j.jval.2017.08.1472
First page :
A642
Section Title :
Disease-Specific Studies
Open access? :
No
Section Order :
1324